The Filing Desk

CervoMed

CRVO · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CRVO · Last close · November 19, 2026
$1.33
Value CervoMed yourself

CervoMed's revenue fell 58.9% to $4 million in fiscal 2025. Its operating margin was −706.2%, down from −187.2% a year earlier. The diluted share count rose 12.0%.

CervoMed Inc. Latest fiscal year ended December 31, 2025 10-K filed March 13, 2026 · 0001437749-26-008259 Updated
Revenue
$4M
58.9%
Operating margin
−706.2%
519.0 pts
Net income
−$27M
 
Free cash flow
—
 
Return on equity
−93.9%
24.0 pts
Market cap
$20M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for stock splits (50-for-1 and 1-for-14.9254), so every year is on today's share basis. Diluted earnings per share for fiscal 2018 and 2022 is left blank: the filing's figure is far from net income divided by diluted shares, so one of them is in the wrong units.

Charts show fiscal years, from the 10-K filings.

What CervoMed does

CervoMed is a clinical-stage biotech company: it develops drugs for age-related brain disorders but has none approved for sale. Its only drug candidate, neflamapimod, is a pill that reaches the brain and blocks an enzyme called p38 alpha, which the company says drives inflammation in the brain and harms the connections between nerve cells.

Its main target is dementia with Lewy bodies (DLB), a progressive dementia with no approved treatment in the US or the European Union. CervoMed focuses on patients whose disease is not mixed with Alzheimer's, a group it believes is more treatable. In November 2025 it said it had agreed with the FDA on key parts of a planned late-stage (Phase 3) trial in DLB, which it plans to start once it has the funding. It is also testing the drug in earlier trials in a form of primary progressive aphasia (a disorder that erodes language), in recovery after stroke and, through a program funded by the UK government and charities, in ALS.

The company has no revenue from product sales. It licenses neflamapimod from Vertex, to which it may owe milestone payments and royalties if the drug succeeds, and it has received a grant from the National Institute on Aging. At the end of 2025 it had 15 full-time employees and relied on outside firms to run its trials and make the drug.

Its biggest risks, as it describes them

  • It needs more money to keep developing neflamapimod and may not be able to raise it on acceptable terms.
  • It depends almost entirely on one drug candidate, which may fail in trials or never be approved.
  • Earlier trial results are not regulatory proof that the drug is safe or works.
  • It relies on outside companies to run its trials and to make the drug, and delays there could hold it back.
  • No patent covers neflamapimod's chemical makeup itself, which may leave room for competing products.
From CervoMed's annual report on Form 10-K, filed March 13, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

CervoMed lost money in fiscal 2025: a net loss of $27 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments371683921
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—−5,920.8x———
Current ratio12.9x——11.1x4.9x
Quick ratio12.9x——11.1x4.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project CervoMed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $3.2 million of CervoMed shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 18, 2026John J AlamCEO & President, Director, 10% ownerBought100,000$1.53$152,621Form 4
Jun 11, 2026Joshua S BogerDirector, 10% ownerBought955,414$3.14$3.0 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''—8.38−12.90
Accruals ratio74.7%0.9%−10.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomeFailFailPass
Debt fell relative to assets———
Current ratio rose——Fail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put CervoMed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CervoMedFY25−58.9%−706.2%————
CAMP4 TherapeuticsFY25436.5%−1,502.4%−852.8%———Compare
Marker TherapeuticsFY25−46.2%−363.4%————Compare
Upstream BioFY2520.4%−5,618.8%−4,675.5%———Compare
Cartesian TherapeuticsFY25−92.8%−5,127.1%−2,838.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——————07104
Revenue growth————————36.3%−58.9%
Gross profit——————————
Research and development756798181922
Operating income−18−11−19−12−16−25−4−8−18−28
Net income−18−1−18−12−14−24−6−2−16−27
Diluted EPS (US$)−0.53−0.58—134,130.181,076,639.461,946,859.00————
Diluted shares (millions)3442162———0389
Cash flow
Cash from operations−11−12−11−10−14−14−3−7−16−23
Capital expenditure00————————
Free cash flow−11−13————————
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1110110011
Balance sheet at fiscal year end
Cash and short-term investments2981418371683921
Debt incl. finance leases2—————————
Total assets1826182428384104323
Total liabilities85343313345
Shareholders' equity92116202535−3373918
Margins and ratios
Gross margin——————————
Operating margin———————−109.3%−187.2%−706.2%
Net margin———————−30.4%−167.3%−673.1%
Free cash flow margin——————————
Rule of 40 (growth + FCF margin)——————————
Return on capital−313.2%—————————
Return on equity−394.5%−9.0%−99.7%−66.0%−63.1%−80.7%——−70.0%−93.9%
Return on assets−182.6%−6.2%−82.8%−55.8%−54.7%−73.5%−27.6%−30.7%−61.4%−81.8%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: CervoMed's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with CervoMed.